Have a feature idea you'd love to see implemented?
Let us know!
CYCN Cyclerion Therapeutics Inc
Price (delayed)
$2.6
Market cap
$7.05M
P/E Ratio
2.06
Dividend/share
N/A
EPS
$1.26
Enterprise value
$2.46M
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates
Highlights
Cyclerion Therapeutics's EPS has soared by 110% YoY
The net income has surged by 110% year-on-year
The equity has soared by 71% YoY but it has contracted by 11% from the previous quarter
The quick ratio has contracted by 9% from the previous quarter
Key stats
What are the main financial stats of CYCN
Market
Valuations
Earnings
Shares outstanding
2.71M
Market cap
$7.05M
Enterprise value
$2.46M
Price to earnings (P/E)
2.06
Price to book (P/B)
0.8
Price to sales (P/S)
N/A
EV/EBIT
0.92
EV/EBITDA
0.92
EV/Sales
N/A
Revenue
$0
EBIT
$2.66M
EBITDA
$2.66M
Free cash flow
-$11.45M
Per share
Balance sheet
Liquidity
EPS
$1.26
Free cash flow per share
-$4.56
Book value per share
$3.24
Revenue per share
$0
TBVPS
$4.01
Total assets
$10.07M
Total liabilities
$1.28M
Debt
$0
Equity
$8.78M
Working capital
$3.43M
Debt to equity
0
Current ratio
3.68
Quick ratio
3.58
Net debt/EBITDA
-1.72
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
24.1%
Return on equity
28.1%
Return on invested capital
67%
Return on capital employed
30.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CYCN stock price
How has the Cyclerion Therapeutics stock price performed over time
Intraday
-1.89%
1 week
3.59%
1 month
-16.13%
1 year
-19.5%
YTD
-22.39%
QTD
0.39%
Financial performance
How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.81M
Net income
$3.01M
Gross margin
N/A
Net margin
N/A
The net income has surged by 110% year-on-year
The operating income has grown by 23% YoY and by 4.3% from the previous quarter
Growth
What is Cyclerion Therapeutics's growth rate over time
Valuation
What is Cyclerion Therapeutics stock price valuation
P/E
2.06
P/B
0.8
P/S
N/A
EV/EBIT
0.92
EV/EBITDA
0.92
EV/Sales
N/A
Cyclerion Therapeutics's EPS has soared by 110% YoY
The equity has soared by 71% YoY but it has contracted by 11% from the previous quarter
The stock's price to book (P/B) is 56% less than its 5-year quarterly average of 1.8 but 14% more than its last 4 quarters average of 0.7
Efficiency
How efficient is Cyclerion Therapeutics business performance
CYCN's return on assets has surged by 114% year-on-year
The company's return on equity has surged by 109% YoY
Dividends
What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CYCN.
Financial health
How did Cyclerion Therapeutics financials performed over time
The current ratio has soared by 156% YoY but it has decreased by 12% from the previous quarter
Cyclerion Therapeutics's total liabilities has plunged by 74% YoY and by 11% from the previous quarter
Cyclerion Therapeutics's debt is 100% less than its equity
The equity has soared by 71% YoY but it has contracted by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.